Suvorexant
- Generic Name
- Suvorexant
- Brand Names
- Belsomra
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23ClN6O2
- CAS Number
- 1030377-33-3
- Unique Ingredient Identifier
- 081L192FO9
- Background
Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
- Indication
Suvorexant is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
- Associated Conditions
- Insomnia
- Associated Therapies
- -
Evaluation of Suvorexant for Reduction of Brain Reactivity in Patients with Cannabis Use Disorder (Pilot Study)
Phase 4
Not yet recruiting
- Conditions
- Cue-reactivityCannabis Use DisorderFunctional MRIOrexin Antagonist
- Interventions
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT06584942
- Locations
- 🇺🇸
Center for Addiction Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States
Orexin s Role in the Neurobiology of Substance Use Disorder
Not Applicable
Recruiting
- Conditions
- Nicotine Dependence
- Interventions
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 140
- Registration Number
- NCT05630781
- Locations
- 🇺🇸
National Institute on Drug Abuse, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath